Infusion Pump Companies

The global infusion pump market is projected to reach USD 28.3 billion by 2030 from USD 19.9 billion in 2025, growing at a CAGR of 7.4% during the forecast period.

The infusion pump market is primarily driven by several key factors, with significant emphasis on the advancement of smart and automated delivery systems. The integration of infusion pumps with electronic health records (EHRs) facilitates auto-programming of medication dosages and ensures real-time documentation of infusion data, enhancing clinical efficiency and accuracy. Additionally, adherence to stringent regulatory standards and cybersecurity protocols for interoperable systems is critical, as it bolsters the safety and reliability of these devices. Globally, there has been a marked increase in the prevalence of chronic illnesses such as diabetes, cancer, and cardiovascular diseases. This trend, coupled with the expanding geriatric demographic, is fueling the growth of the infusion pump market. Moreover, the escalating incidence of chronic conditions has heightened the demand for home care treatments, which are essential for improving patient compliance and outcomes. This shift towards home healthcare underscores the need for innovative infusion solutions that cater to a diverse patient population while ensuring optimal therapeutic management.

The prominent players in the infusion pump market are Becton, Dickinson and Company (US), Baxter (US), B. Braun SE (Germany), ICU Medical, Inc. (US), Fresenius Kabi AG (Germany), Medtronic (Ireland), Terumo Corporation (Japan), NIPRO (Japan), AVNS (US), and Insulet Corporation (US). These companies have implemented a variety of growth strategies, both organic and inorganic, including the introduction of new products, the formation of strategic partnerships, and penetration into emerging markets. These initiatives are aimed at enhancing their market share and diversifying their portfolios. In January 2025, Tandem Diabetes Care, Inc. announced a strategic multiyear partnership with the University of Virginia Center for Diabetes Technology, focusing on the advancement of fully automated insulin delivery systems. This collaboration aims to enhance diabetes management by integrating sophisticated automated insulin delivery (AID) algorithms into cutting-edge medical devices. Additionally, in September 2024, BD completed its acquisition of Edwards Lifesciences Corporation. This strategic move is expected to significantly broaden BD’s portfolio of smart connected care solutions, particularly in the realm of monitoring technologies and AI-driven clinical decision-making tools. The integration of these capabilities will facilitate the development of advanced closed-loop monitoring and treatment systems, bolstering the efficacy of diabetes care.

To know about the assumptions considered for the study download the pdf brochure

Becton, Dickinson and Company (BD) is a prominent player in the medical technology sector, delivering a diverse array of medical devices, diagnostic solutions, and interventional therapies across more than 190 countries. The organization operates through three principal business segments: Medication Delivery Solutions, Medication Management Solutions, and Pharmaceutical Systems. Within these segments, BD provides a comprehensive range of infusion systems and associated disposables. Recognized for its commitment to innovation, BD has established a robust presence with several subsidiaries located in Germany, Canada, and the US. The company’s significant contributions to improving patient care and advancements in health technology led to its classification in the top 25% of the most innovative US companies by Fortune in 2025. BD has employed both organic growth strategies and strategic acquisitions to enhance its market position. In 2024, the company allocated over USD 10 million to bolster its US manufacturing capabilities, significantly increasing production capacity for essential medical devices such as syringes, needles, and IV catheters. Following this, BD plans to invest an additional USD 30 million in 2025 to expand its IV-line manufacturing operations in Utah, further solidifying its capability to meet the demands of the healthcare market.

Baxter is a leading entity in the healthcare sector, with a strong emphasis on medical devices, pharmaceuticals, and biotechnology aimed at addressing various diseases and chronic conditions. The company's expertise spans acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, as well as surgical hemostatic and sealing agents. Baxter operates through distinct segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals, underscoring its multifaceted approach to healthcare solutions. With a significant global footprint in over 100 countries, the company is dedicated to enhancing patient outcomes through software innovations and robust safety protocols. In a recent development, Baxter attained FDA 510(k) clearance in April 2024 for its Novum IQ large-volume infusion pump, enhanced with Dose IQ Safety Software, which introduces advanced connectivity features to improve infusion safety and management.

Market Ranking:

The top five companies for the infusion pump market are Becton, Dickinson and Company (BD) (US), Baxter (US), B. Braun SE (Germany), ICU Medical, Inc. (US), and Fresenius Kabi AG (Germany). BD (US) excels with a robust and varied product portfolio that encompasses advanced medical devices, comprehensive diagnostics, and innovative biosciences solutions, all bolstered by strategic alliances. Baxter (US) leverages its prowess in R&D, alongside software innovations and safety enhancements, to uphold a formidable market presence. B. Braun SE (Germany) strengthens its competitive edge through digital health capabilities and an increasingly expansive global footprint. ICU Medical, Inc. (US) enhances its market position by diversifying its product offerings, specifically in syringe and ambulatory infusion systems, while focusing on increased digital integration across its devices. Fresenius Kabi AG (Germany) capitalizes on innovation and digitalization strategies to address distinct clinical needs and to improve interoperability among its solutions.

Related Reports:

Infusion Pump Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Insulin, Syringe, Volumetric, Enteral, PCA Pump)), Technology (Traditional, Specialty), Mode (Stationary, Portable), Application (Cancer, Diabetes) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com